Dupuytren’s Disease Market Synopsis:
Dupuytren’s Disease Market Size Was Valued at USD 4.2 Billion in 2023, and is Projected to Reach USD 5.8 Billion by 2032, Growing at a CAGR of 4.5% From 2024-2032.
Dupuytrens disease is a disease affecting the hand that involves an abnormally progressive contracture of the connective tissue just below the skin resulting in formation of nodules and cords. First, the condition principally involves the palmar fascia where the fingers tend to slowly curl towards the palm thus restricted hand motion. It is most often seen in the elderly and is more so in the people of Northern European origin. The market for Dupuytren’s disease treatments is therefore growing, particularly stimulated by innovations that can help relieve the symptoms and the resulting limitations in hand movements and disability.
The market for the treatment of Dupuytren’s disease has been constantly rising thanks to the enhanced patient population acceptance, increased global awareness, and innovations in treatment. In the past, the treatments for Dupuytren’s disease were surgical procedures including open incisions of the contracted fascia known as fasciotomy or excision of the affected fascia known as fasciectomy. However, in recent years, there are minimally invasive procedures like Eigensulfat-Konzentrat-Injektiv (collagenase Clostridium histolyticum), needle Aponenervitomy and radiotherapy. These sources of aortic conduits are less likely to have issues that complicate the cases or slow down the patient’s healing process which means that this increases the number of people who can get treatment.
The market is also growing by the increasing rate of risks factors such as age, family history and some inherited genes. Further, as the geriatric population expands progressively around the world, the need for appropriate treatment is likely to rise sharply. The development of other minimally invasive surgical procedures are likely to steer the market since they provide patients with a non-invasive option to conventional surgery and surgery that is expensive and time-consuming. Additionally, ongoing development of more specific biologic drugs and gene therapy make people believe that more effective and long-lasting ways of Dupuytren’s disease treatment can be found in near future.

Dupuytren’s Disease Market Trend Analysis:
Increasing Adoption of Minimally Invasive Treatments
- Another important observed trend in the growth of the market for Dupuytrens disease treatment concerns the growing popularity of minimally invasive approaches. This is due to the progress of technology, and the change in the demands of the patient as well as care provider for surgical procedures that take least time to heal and have minimal risk factors. Less invasive treatments like collagenase injections and needle aponeurotomy are becoming popular because we get a lot of benefits when compare with conventional operative procedures like less pain, minimal complications and early return to the activities. Since both the healthcare providers and the patients are looking for value based methods of treatment and care, the use of these minimally invasive treatments will further rise in the future.
- Besides, new improved injections therapies and research of gene treatment methods act as stimuli for this trend. In light of recent biologic agents under study to treat Dupuytren’s disease more thoroughly and decrease the actual molecular pathways that cause the sickness, one can assume future improvements in the approach to its eradication. Of the trends that are likely to encourage the development and growth of the Dupuytren’s disease market in the future years, this one seemed to be promising.
Expanding Market in Emerging Economies
- Another clear chance in the market of Dupuytren’s disease lies in increasing availability of the medications in developing countries. A steadily rising middle-class populace along with enhanced healthcare facilities and accessibility to innovative medical treatments make Asian-Pacific, Latin American and East European nations a rising market for Dupuytren’s disease remedies. Most of these regions have a big population base with dominant aging people who experience Dupuytrens disease. The potential for market development in these areas is further complemented by raising popularity of minimally invasive procedures and progressive shift of demand for contemporary healthcare solutions in these markets.
- Besides, there will be market penetration due to adoption of low cost solutions and through regional integration to increase healthcare access. So while governments and healthcare organisations dedicate their funding towards making healthcare more accessible, medical equipment manufacturing firms and pharmaceutical companies are given the opportunity of exploring the market and extending their portfolio of products to these new markets. If corporations put this in focus and develop simple and within access treatments then there are a lot of open opportunities in these prospering areas of the world.
Dupuytren’s Disease Market Segment Analysis:
Dupuytren’s Disease Market is Segmented on the basis of Disease type, Type, end user, and region
By Disease Type, Type I segment is expected to dominate the market during the forecast period
- In terms of type of disease, it is anticipated that Type I segments will share the largest growth sales during the forecast period because of the rising incidence of Type I diabetes and other ailments belonging to the Type I disease classification. The one side, some reasons include; Development of improved diagnostic tools, emerging need for the specialized care, and an ever-increasing patient pool that requires regular follow-up. Furthermore, with a growing emphasis being placed on bringing novel treatments and methods of controlling Type I diseases to market, the Type I disease segments should see a great deal of future growth.
- The growth forecast for the Type I disease segment is also increased by the augmentation in disease awareness and early diagnosis and an enhanced focus on individualized treatment strategies. Fueled by escalating international interest in the advancement of the healthcare system and increasing availability of specialized services, Type I diseases are getting more attention from physicians and officials alike. Also, as new technological advancements continue to emerge in the form of insulin pumps and continuous glucose monitoring systems and other related equipment the Type I disease segments would continue to dominate the market and offer better management solutions for patients thereby enhancing their quality of life across the globe.
By Type, Diagnosis segment expected to held the largest share
- Based on the type of device, the diagnosis segment is expected to dominate the market throughout the forecast period. This growth however can be attributed to the higher demand for early and accurate diagnostic lab tests due to advancements in lab diagnostics. The application of such technologies as molecular diagnostics, imaging, and molecular genetics to learn about a disease and its causes has provided faster and more accurate ability to diagnose an ailment across the health field. The diagnosis segment is expected to grow at a significant rate due to increase in preference of early diagnosis by the healthcare providers for better treatment and lesser overall healthcare expenses in future.
- Also, the increasing frequency of chronic diseases and the increasing acceptance of routine health checkup have put more focus on the diagnosis segment. When patients are looking for ways to prevent illnesses, the use of diagnostic tests – general and specific – remains on the rise. Moreover, advanced technologies in AI and machine learning are improving the character and speed of diagnosis and therefore allowing the diagnosis of diseases at an early stage as well as with a high degree of probability by different healthcare workers. With these developments, the diagnosis segment looks destined to be an important stakeholder in the healthcare market until the forecast period.
Dupuytren’s Disease Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- Nevertheless, in the year 2023, North America specifically the United States occupies the highest market share in the Dupuytren’s disease market. The region has the largest market share, accounting for approximately 40-45% of the global market because of factors such as high incidences of the disease, good access to modern health care, and major market participants. The shift in the concern of the healthcare system of the United States towards patient care, coupled with high research and development activities is among the factors that has led to North America emerging as the largest market for Dupuytren’s disease treatments.
- Rising number of patients in the region is an important factor Accurate aware of the treatments available for them along with the increasing old age population strengthens the market position. Also, inclusion of minimally invasive treatments like collagenase injections is anticipated to consolidate market growth in the region of North America because of constant demand for economic yet efficient therapies among the patient base and principal care providers. Currently, this region has exhibited a well-developed healthcare industry and the advanced medical technology, pharmaceuticals and medical device companies will help this region to retain market leadership in the global Dupuytren’s disease treatment market in future years as well.
Active Key Players in the Dupuytren’s Disease Market:
- AbbVie Inc. (U.S.)
- Bayer AG (Germany)
- Bioventus (U.S.)
- Endo International (Ireland)
- Horizon Therapeutics (Ireland)
- Ipsen S.A. (France)
- Luminex Corporation (U.S.)
- Medytox, Inc. (South Korea)
- Merz Pharmaceuticals (Germany)
- Neovacs (France)
- Orthofix Medical Inc. (U.S.)
- Pfizer, Inc. (U.S.)
- Procept BioRobotics (U.S.)
- Revance Therapeutics, Inc. (U.S.)
- Sanofi S.A. (France)
- Other Active Players
Dupuytren’s Disease Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 4.2 Billion |
Forecast Period 2024-32 CAGR: |
4.5 % |
Market Size in 2032: |
USD 5.8 Billion |
Segments Covered: |
By Disease Type |
|
|
By Type |
|
||
By End User |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Dupuytren’s Disease Market by By Disease Type (2018-2032)
4.1 Dupuytren’s Disease Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Type I
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Type II
4.5 Type III
Chapter 5: Dupuytren’s Disease Market by By Type (2018-2032)
5.1 Dupuytren’s Disease Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Diagnosis
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Physical Examination
5.5 X-ray
5.6 Treatment
5.7 Surgery
5.8 Radiation Therapy
5.9 Needle Aponeurotomy
5.10 Steroid Shot
5.11 Enzyme Injection
5.12 Occupational Therapy
5.13 Others
Chapter 6: Dupuytren’s Disease Market by By End User (2018-2032)
6.1 Dupuytren’s Disease Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Clinics
6.5 Academic & Research Institute
6.6 Others
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Dupuytren’s Disease Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBVIE INC. (U.S.)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 BAYER AG (GERMANY)
7.4 BIOVENTUS (U.S.)
7.5 ENDO INTERNATIONAL (IRELAND)
7.6 HORIZON THERAPEUTICS (IRELAND)
7.7 IPSEN S.A. (FRANCE)
7.8 LUMINEX CORPORATION (U.S.)
7.9 MEDYTOX INC. (SOUTH KOREA)
7.10 MERZ PHARMACEUTICALS (GERMANY)
7.11 NEOVACS (FRANCE)
7.12 ORTHOFIX MEDICAL INC. (U.S.)
7.13 PFIZER INC. (U.S.)
7.14 PROCEPT BIOROBOTICS (U.S.)
7.15 REVANCE THERAPEUTICS INC. (U.S.)
7.16 SANOFI S.A. (FRANCE)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Dupuytren’s Disease Market By Region
8.1 Overview
8.2. North America Dupuytren’s Disease Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By By Disease Type
8.2.4.1 Type I
8.2.4.2 Type II
8.2.4.3 Type III
8.2.5 Historic and Forecasted Market Size By By Type
8.2.5.1 Diagnosis
8.2.5.2 Physical Examination
8.2.5.3 X-ray
8.2.5.4 Treatment
8.2.5.5 Surgery
8.2.5.6 Radiation Therapy
8.2.5.7 Needle Aponeurotomy
8.2.5.8 Steroid Shot
8.2.5.9 Enzyme Injection
8.2.5.10 Occupational Therapy
8.2.5.11 Others
8.2.6 Historic and Forecasted Market Size By By End User
8.2.6.1 Hospitals
8.2.6.2 Clinics
8.2.6.3 Academic & Research Institute
8.2.6.4 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Dupuytren’s Disease Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By By Disease Type
8.3.4.1 Type I
8.3.4.2 Type II
8.3.4.3 Type III
8.3.5 Historic and Forecasted Market Size By By Type
8.3.5.1 Diagnosis
8.3.5.2 Physical Examination
8.3.5.3 X-ray
8.3.5.4 Treatment
8.3.5.5 Surgery
8.3.5.6 Radiation Therapy
8.3.5.7 Needle Aponeurotomy
8.3.5.8 Steroid Shot
8.3.5.9 Enzyme Injection
8.3.5.10 Occupational Therapy
8.3.5.11 Others
8.3.6 Historic and Forecasted Market Size By By End User
8.3.6.1 Hospitals
8.3.6.2 Clinics
8.3.6.3 Academic & Research Institute
8.3.6.4 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Dupuytren’s Disease Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By By Disease Type
8.4.4.1 Type I
8.4.4.2 Type II
8.4.4.3 Type III
8.4.5 Historic and Forecasted Market Size By By Type
8.4.5.1 Diagnosis
8.4.5.2 Physical Examination
8.4.5.3 X-ray
8.4.5.4 Treatment
8.4.5.5 Surgery
8.4.5.6 Radiation Therapy
8.4.5.7 Needle Aponeurotomy
8.4.5.8 Steroid Shot
8.4.5.9 Enzyme Injection
8.4.5.10 Occupational Therapy
8.4.5.11 Others
8.4.6 Historic and Forecasted Market Size By By End User
8.4.6.1 Hospitals
8.4.6.2 Clinics
8.4.6.3 Academic & Research Institute
8.4.6.4 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Dupuytren’s Disease Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By By Disease Type
8.5.4.1 Type I
8.5.4.2 Type II
8.5.4.3 Type III
8.5.5 Historic and Forecasted Market Size By By Type
8.5.5.1 Diagnosis
8.5.5.2 Physical Examination
8.5.5.3 X-ray
8.5.5.4 Treatment
8.5.5.5 Surgery
8.5.5.6 Radiation Therapy
8.5.5.7 Needle Aponeurotomy
8.5.5.8 Steroid Shot
8.5.5.9 Enzyme Injection
8.5.5.10 Occupational Therapy
8.5.5.11 Others
8.5.6 Historic and Forecasted Market Size By By End User
8.5.6.1 Hospitals
8.5.6.2 Clinics
8.5.6.3 Academic & Research Institute
8.5.6.4 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Dupuytren’s Disease Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By By Disease Type
8.6.4.1 Type I
8.6.4.2 Type II
8.6.4.3 Type III
8.6.5 Historic and Forecasted Market Size By By Type
8.6.5.1 Diagnosis
8.6.5.2 Physical Examination
8.6.5.3 X-ray
8.6.5.4 Treatment
8.6.5.5 Surgery
8.6.5.6 Radiation Therapy
8.6.5.7 Needle Aponeurotomy
8.6.5.8 Steroid Shot
8.6.5.9 Enzyme Injection
8.6.5.10 Occupational Therapy
8.6.5.11 Others
8.6.6 Historic and Forecasted Market Size By By End User
8.6.6.1 Hospitals
8.6.6.2 Clinics
8.6.6.3 Academic & Research Institute
8.6.6.4 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Dupuytren’s Disease Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By By Disease Type
8.7.4.1 Type I
8.7.4.2 Type II
8.7.4.3 Type III
8.7.5 Historic and Forecasted Market Size By By Type
8.7.5.1 Diagnosis
8.7.5.2 Physical Examination
8.7.5.3 X-ray
8.7.5.4 Treatment
8.7.5.5 Surgery
8.7.5.6 Radiation Therapy
8.7.5.7 Needle Aponeurotomy
8.7.5.8 Steroid Shot
8.7.5.9 Enzyme Injection
8.7.5.10 Occupational Therapy
8.7.5.11 Others
8.7.6 Historic and Forecasted Market Size By By End User
8.7.6.1 Hospitals
8.7.6.2 Clinics
8.7.6.3 Academic & Research Institute
8.7.6.4 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
Dupuytren’s Disease Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 4.2 Billion |
Forecast Period 2024-32 CAGR: |
4.5 % |
Market Size in 2032: |
USD 5.8 Billion |
Segments Covered: |
By Disease Type |
|
|
By Type |
|
||
By End User |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Frequently Asked Questions :
The forecast period in the Dupuytren’s Disease Market research report is 2024-2032.
AbbVie Inc. (U.S.), Bayer AG (Germany), Bioventus (U.S.), Endo International (Ireland), Horizon Therapeutics (Ireland), Ipsen S.A. (France), Luminex Corporation (U.S.), Medytox, Inc. (South Korea), Merz Pharmaceuticals (Germany), Neovacs (France), Orthofix Medical Inc. (U.S.), Pfizer, Inc. (U.S.), Procept BioRobotics (U.S.), Revance Therapeutics, Inc. (U.S.), Sanofi S.A. (France), and Other Active Players.
The Dupuytren’s Disease Market is segmented into Disease Type, by Type End User and region. By Disease Type, the market is categorized into Type I ,Type II ,Type III . By Type, the market is categorized into Diagnosis,Physical Examination,X-ray ,Treatment, Surgery,Radiation Therapy ,Needle Aponeurotomy ,Steroid Shot ,Enzyme Injection ,Occupational Therapy ,Others. By End User, the market is categorized into Hospitals ,Clinics, Academic & Research Institute ,Others. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Dupuytrens disease is a disease affecting the hand that involves an abnormally progressive contracture of the connective tissue just below the skin resulting in formation of nodules and cords. First, the condition principally involves the palmar fascia where the fingers tend to slowly curl towards the palm thus restricted hand motion. It is most often seen in the elderly and is more so in the people of Northern European origin. The market for Dupuytren’s disease treatments is therefore growing, particularly stimulated by innovations that can help relieve the symptoms and the resulting limitations in hand movements and disability.
Dupuytren’s Disease Market Size Was Valued at USD 4.2 Billion in 2023, and is Projected to Reach USD 5.8 Billion by 2032, Growing at a CAGR of 4.5% From 2024-2032.